Immune checkpoint antibodies that augment the programmed cell death protein 1 (PD-1)/PD-
L1 pathway have demonstrated antitumor activity across multiple malignancies, and gained …

The increased target specificity of epidermal growth factor receptor (EGFR) inhibitors
(EGFRIs) is associated with the reduction or abolition of nonspecific and haematopoietic …

Epidermal growth factor receptor inhibitors (EGFRIs) have demonstrated improved overall
survival in patients with non-small cell lung cancer, pancreatic cancer, and colorectal …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Purpose Panitumumab, a fully human monoclonal antibody targeting the epidermal growth
factor receptor (EGFR), is approved in the United States and Europe for the treatment of …

Background Epidermal growth factor receptor inhibitors (EGFRI) produce various
dermatologic side effects in the majority of patients, and guidelines are crucial for the …

Abstract Ulixertinib (BVD-523) is an ERK1/2 kinase inhibitor with potent preclinical activity in
BRAF-and RAS-mutant cell lines. In this multicenter phase I trial (NCT01781429), 135 …

Dermatologic adverse events to cancer therapies have become more prevalent and may to
lead to dose modifications or discontinuation of life-saving or prolonging treatments. This …

Immune checkpoint inhibitors have emerged as a pillar in the management of advanced
malignancies. However, nonspecific immune activation may lead to immune-related adverse …

Background BRAF V600E is the genetic lesion underlying hairy-cell leukemia. We assessed
the safety and activity of the oral BRAF inhibitor vemurafenib in patients with hairy-cell …